ISRG 2023 Q2 Conference Call Recap

Sales of $1460 million

Sales growth rate +18% yoy

Operating margin 29%

The surgical growth rate is +22%, and benign diseases in general surgery and gynecology are strong

331 systems were introduced, up from 279 in Q2 last year

・Future growth points

Adoption of lung cancer surgery has increased

Increased initial adoption of lung biopsies using the Ion endoluminal system (something like a soft, thin bronchoscope)

Clinical research is increasing

Well honestly, the content hasn't changed much from recent conference calls 😅

However, sales have been steadily increasing by double digits, and the operating profit margin is over 20%, so the horizons are pretty high.

Lung cancer has the highest mortality rate of Japanese people, and if diagnostic treatment for suspected metastasis is included, the number of surgeries is high, so I'm expecting quite a bit 👍

Stock prices have dropped since the announcement, but since I'm thinking about the long term, I'm going to buy things here and there while watching my funds